FLT3-ITD mutation had been considered as a negative prognostic marker, used for AML risk stratification and disease monitoring via MRD, with the clinical importance of early detection at diagnosis and again at relapse [2]. The gene discussed is FLT3; the disease is acute myeloid leukemia.